Glaxosmithkline and Elbion to Collaborate on Development and Commercialisation of a new DE IV Inhibitor
25 Jan 2005 -
GlaxoSmithKline plc (GSK) and elbion AG announce that they have signed a worldwide agreement to collaborate on the development and commercialisation of elbion's phosphodiesterase (PDE) IV inhibitor, AWD 12-281 and associated back-up compounds. AWD 12-281 is currently in phase II clinical studies by the intra nasal delivery route for allergic rhinitis and phase I studies by inhaled delivery for asthma
and chronic obstructive pulmonary disease (COPD).
Top
Contact
Print version
PDF version
Send article
RSS-Feed